Bio Path OTC Stock Top Insiders

Bio Path Management Team Effectiveness

The company has return on total asset (ROA) of (1.9409) % which means that it has lost $1.9409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5974) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. Almost 92.59 percent of Bio Path outstanding shares are held by general public with 7.41 % by other corporate entities. Some institutional investors establish a significant position in otc stocks such as Bio Path in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Bio Path, and when they decide to sell, the otc stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Bio Path Workforce Comparison

Bio Path Insider Trading

Bio Path Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Bio Path Holdings often depends on how effective the management is. Bio Path management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in Bio Path's official financial statements typically reflect Bio Path's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Bio Path's quantitative information. For example, before you start analyzing numbers published by Bio accountants, it's essential to understand Bio Path's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.

When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.